Beam Therapeutics (BEAM) Stock Forecast & Price Target

Compare

1,922 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BEAM Analyst Ratings

Strong Buy

9 Buy

2 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Beam

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BEAM Stock 12 Month Forecast

Average Price Target

$40.63

▲(68.38% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $40.63 with a high forecast of $80.00 and a low forecast of $20.00. The average price target represents a 68.38% change from the last price of $24.13.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","48":"$48","81":"$81","31.5":"$31.5","64.5":"$64.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,31.5,48,64.5,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.31,21.209230769230768,26.108461538461537,31.007692307692306,35.90692307692308,40.80615384615385,45.70538461538462,50.604615384615386,55.503846153846155,60.403076923076924,65.30230769230769,70.20153846153846,75.10076923076923,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.31,18.18076923076923,20.05153846153846,21.92230769230769,23.793076923076924,25.66384615384615,27.534615384615385,29.405384615384616,31.276153846153846,33.14692307692307,35.01769230769231,36.88846153846154,38.75923076923077,{"y":40.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.31,16.59384615384615,16.877692307692307,17.16153846153846,17.445384615384615,17.729230769230767,18.013076923076923,18.296923076923076,18.58076923076923,18.864615384615384,19.14846153846154,19.432307692307692,19.716153846153848,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.41,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.34,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.64,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.83,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.53,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.31,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$80.00

Average Price Target$40.63

Lowest Price Target$20.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$80

Buy

231.54%

Upside

Reiterated

09/17/25

Beam Therapeutics: Strong Buy Rating Backed by Advancements in Genetic Medicine ProgramsWe reiterate our Buy rating and $80 price target on BEAM.

William Pickering

Bernstein

$32

Buy

32.62%

Upside

Assigned

09/03/25

Bernstein Issues a Buy Rating on Beam Therapeutics (BEAM)

Mani Foroohar

Leerink Partners

―

Buy

―

Reiterated

09/03/25

We continue to see the risk/reward skewed favorably into updated data early-26.

Alec Stranahan

Bank of America Securities

$43

Buy

78.20%

Upside

Reiterated

09/03/25

Analysts Offer Insights on Healthcare Companies: Treace Medical Concepts (NASDAQ: TMCI), Beam Therapeutics (NASDAQ: BEAM) and Incyte (NASDAQ: INCY)

Rick Bienkowski

Cantor Fitzgerald

―

Buy

―

Reiterated

08/19/25

Cantor Fitzgerald Remains a Buy on Beam Therapeutics (BEAM)Cantor Fitzgerald analyst Rick Bienkowski reiterated an Overweight rating on Beam Therapeutics Inc (NASDAQ: BEAM).

Soumit Roy

JonesTrading

$34→$25

Buy

3.61%

Upside

Reiterated

08/08/25

Beam Therapeutics: Strong Buy Rating Backed by Promising Trials and Solid Financial Position

Gena Wang

Barclays

$25→$21

Hold

-12.97%

Downside

Reiterated

08/06/25

Barclays Sticks to Its Hold Rating for Beam Therapeutics (BEAM)

William Maughan

Clear Street

$34

Buy

40.90%

Upside

Reiterated

08/05/25

Beam Therapeutics (BEAM) Gets a Buy from Clear Street

Sami Corwin

William Blair

―

Buy

―

Reiterated

08/05/25

Beam Therapeutics (BEAM) Gets a Buy from William Blair

Yanan Zhu

Wells Fargo

$70

Buy

190.10%

Upside

Reiterated

08/05/25

Positive Developments and Financial Strength Bolster Beam Therapeutics' Buy Rating

Luca Issi

RBC Capital

$20

Hold

-17.12%

Downside

Reiterated

08/05/25

RBC Capital Sticks to Its Hold Rating for Beam Therapeutics (BEAM)

Eric Joseph

J.P. Morgan

$25.61→$48

Buy

98.92%

Upside

Reiterated

06/25/25

JPMorgan's Bullish Outlook on Beam Therapeutics: Promising Genetic Base-Editing Platform and Strategic Growth Prospects

David Nierengarten

Wedbush

$57

Buy

136.22%

Upside

Reiterated

06/16/25

Beam Therapeutics (BEAM) Gets a Buy from Wedbush

Debjit Chattopadhyay

Guggenheim

$78→$55

Buy

127.93%

Upside

Reiterated

05/07/25

Beam Therapeutics Inc (BEAM) PT Lowered to $55 at GuggenheimGuggenheim analyst Debjit Chattopadhyay lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $55.00 (from $78.00) while maintaining a Buy rating.

Greg Harrison

Scotiabank

$40

Buy

65.77%

Upside

Reiterated

04/07/25

Beam Therapeutics (BEAM) Gets a Buy from Scotiabank

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$80

Buy

231.54%

Upside

Reiterated

09/17/25

Beam Therapeutics: Strong Buy Rating Backed by Advancements in Genetic Medicine ProgramsWe reiterate our Buy rating and $80 price target on BEAM.

William Pickering

Bernstein

$32

Buy

32.62%

Upside

Assigned

09/03/25

Bernstein Issues a Buy Rating on Beam Therapeutics (BEAM)

Mani Foroohar

Leerink Partners

―

Buy

―

Reiterated

09/03/25

We continue to see the risk/reward skewed favorably into updated data early-26.

Alec Stranahan

Bank of America Securities

$43

Buy

78.20%

Upside

Reiterated

09/03/25

Analysts Offer Insights on Healthcare Companies: Treace Medical Concepts (NASDAQ: TMCI), Beam Therapeutics (NASDAQ: BEAM) and Incyte (NASDAQ: INCY)

Rick Bienkowski

Cantor Fitzgerald

―

Buy

―

Reiterated

08/19/25

Cantor Fitzgerald Remains a Buy on Beam Therapeutics (BEAM)Cantor Fitzgerald analyst Rick Bienkowski reiterated an Overweight rating on Beam Therapeutics Inc (NASDAQ: BEAM).

Soumit Roy

JonesTrading

$34→$25

Buy

3.61%

Upside

Reiterated

08/08/25

Beam Therapeutics: Strong Buy Rating Backed by Promising Trials and Solid Financial Position

Gena Wang

Barclays

$25→$21

Hold

-12.97%

Downside

Reiterated

08/06/25

Barclays Sticks to Its Hold Rating for Beam Therapeutics (BEAM)

William Maughan

Clear Street

$34

Buy

40.90%

Upside

Reiterated

08/05/25

Beam Therapeutics (BEAM) Gets a Buy from Clear Street

Sami Corwin

William Blair

―

Buy

―

Reiterated

08/05/25

Beam Therapeutics (BEAM) Gets a Buy from William Blair

Yanan Zhu

Wells Fargo

$70

Buy

190.10%

Upside

Reiterated

08/05/25

Positive Developments and Financial Strength Bolster Beam Therapeutics' Buy Rating

Luca Issi

RBC Capital

$20

Hold

-17.12%

Downside

Reiterated

08/05/25

RBC Capital Sticks to Its Hold Rating for Beam Therapeutics (BEAM)

Eric Joseph

J.P. Morgan

$25.61→$48

Buy

98.92%

Upside

Reiterated

06/25/25

JPMorgan's Bullish Outlook on Beam Therapeutics: Promising Genetic Base-Editing Platform and Strategic Growth Prospects

David Nierengarten

Wedbush

$57

Buy

136.22%

Upside

Reiterated

06/16/25

Beam Therapeutics (BEAM) Gets a Buy from Wedbush

Debjit Chattopadhyay

Guggenheim

$78→$55

Buy

127.93%

Upside

Reiterated

05/07/25

Greg Harrison

Scotiabank

$40

Buy

65.77%

Upside

Reiterated

04/07/25

Beam Therapeutics (BEAM) Gets a Buy from Scotiabank

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Beam Therapeutics

1 Month

xxx

Success Rate

8/12 ratings generated profit

Average Return

+2.46%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +2.46% per trade.

3 Months

xxx

Success Rate

9/12 ratings generated profit

Average Return

+6.10%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +6.10% per trade.

1 Year

Yanan ZhuWells Fargo

Success Rate

9/16 ratings generated profit

Average Return

-2.05%

reiterated a buy rating 2 months ago

Copying Yanan Zhu's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of -2.05% per trade.

2 Years

xxx

Success Rate

6/12 ratings generated profit

Average Return

+15.81%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +15.81% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BEAM Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BEAM has received 17 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. BEAM average Analyst price target in the past 3 months is 40.63.

Each month's total comprises the sum of three months' worth of ratings.

BEAM Financial Forecast

BEAM Earnings Forecast

Next quarter’s earnings estimate for BEAM is -$1.05 with a range of -$1.28 to -$0.79. The previous quarter’s EPS was -$1.00. BEAM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year BEAM has Preformed in-line its overall industry.

BEAM Sales Forecast

Next quarter’s sales forecast for BEAM is $12.49M with a range of $8.00M to $25.00M. The previous quarter’s sales results were $8.47M. BEAM beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year BEAM has Preformed in-line its overall industry.

BEAM Stock Forecast FAQ

What is BEAM’s average 12-month price target, according to analysts?

Based on analyst ratings, Beam Therapeutics’s 12-month average price target is 40.63.

What is BEAM’s upside potential, based on the analysts’ average price target?

Beam Therapeutics has 68.38% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BEAM a Buy, Sell or Hold?

Beam Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 2 hold ratings and 0 sell ratings.

What is Beam Therapeutics’s price target?

The average price target for Beam Therapeutics is 40.63. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $20.00. The average price target represents 68.38% Increase from the current price of $24.13.

What do analysts say about Beam Therapeutics?

Beam Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of BEAM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Beam Therapeutics (BEAM) Stock Forecast & Price Target

BEAM Analyst Ratings

BEAM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Beam Therapeutics

BEAM Analyst Recommendation Trends

BEAM Financial Forecast

BEAM Earnings Forecast

BEAM Sales Forecast

BEAM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts